去年，BioMarin Pharmaceutical Inc表现最佳的业务板块Voxzogo实现营收926.92M美元。United States的营收贡献最高，去年达到1.10B美元。最近一个季度，截至2026-06-30，BioMarin Pharmaceutical Inc表现最佳的业务板块Voxzogo实现营收252.53M美元。United States的营收贡献最高，达到371.07M美元。

业务

营业收入

占比

年报

年报

单季报

Voxzogo

Vimizim

Naglazyme

Palynziq

Aldurazyme

Brineura

Kuvan

Royalty and other revenue

Roctavian

Firdapse

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Voxzogo

926.92M(28.78%)

735.09M(25.76%)

469.88M(19.42%)

169.13M(8.28%)

5.86M(0.33%)

--(--)

Vimizim

792.05M(24.59%)

739.78M(25.92%)

701.05M(28.98%)

663.74M(32.50%)

623.14M(34.94%)

544.26M(30.14%)

544.35M(32.77%)

481.98M(32.78%)

Naglazyme

485.40M(15.07%)

479.58M(16.80%)

420.29M(17.37%)

443.79M(21.73%)

380.45M(21.33%)

391.30M(21.67%)

374.33M(22.54%)

345.85M(23.52%)

Palynziq

433.31M(13.45%)

355.05M(12.44%)

303.92M(12.56%)

255.03M(12.49%)

237.47M(13.32%)

170.98M(9.47%)

86.86M(5.23%)

12.17M(0.83%)

Aldurazyme

208.51M(6.47%)

183.89M(6.44%)

131.25M(5.43%)

128.42M(6.29%)

122.77M(6.88%)

130.11M(7.20%)

97.81M(5.89%)

135.10M(9.19%)

Brineura

186.40M(5.79%)

169.08M(5.92%)

161.89M(6.69%)

154.33M(7.56%)

128.03M(7.18%)

110.19M(6.10%)

72.00M(4.33%)

39.89M(2.71%)

Kuvan

99.53M(3.09%)

120.90M(4.24%)

180.77M(7.47%)

227.58M(11.14%)

285.78M(16.02%)

457.74M(25.35%)

463.35M(27.90%)

433.58M(29.49%)

Royalty and other revenue

53.49M(1.66%)

44.47M(1.56%)

46.69M(1.93%)

--(--)

Roctavian

35.64M(1.11%)

26.07M(0.91%)

3.49M(0.14%)

--(--)

Firdapse

--(--)

1.29M(0.07%)

22.35M(1.35%)

21.79M(1.48%)

地区

营业收入

占比

年报

年报

单季报

United States

Europe

Rest of the world

Latin America

ALDURAZYME net product revenues marked by Sanofi

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

1.10B(34.88%)

924.81M(32.92%)

771.31M(32.51%)

684.28M(35.76%)

657.70M(36.88%)

912.38M(49.04%)

778.44M(45.68%)

696.79M(46.73%)

Europe

874.33M(27.60%)

829.03M(29.51%)

669.33M(28.21%)

650.95M(34.02%)

558.95M(31.34%)

518.47M(27.87%)

509.19M(29.88%)

436.43M(29.27%)

Rest of the world

544.47M(17.19%)

493.63M(17.57%)

468.21M(19.73%)

311.57M(16.28%)

375.69M(21.07%)

223.75M(12.03%)

197.63M(11.60%)

172.94M(11.60%)

Latin America

435.48M(13.75%)

378.08M(13.46%)

332.44M(14.01%)

266.80M(13.94%)

191.15M(10.72%)

205.86M(11.07%)

218.79M(12.84%)

185.05M(12.41%)

ALDURAZYME net product revenues marked by Sanofi

208.51M(6.58%)

183.89M(6.55%)

131.25M(5.53%)

--(--)